CancerPhase 2NCT07346677
Comparing of Sesame Oil, Nitroglycerin Ointment, and Aloe Vera Gel
A Phase 2 study testing Sesame Oil, Aloe vera gel and nitroglycerin ointment in people with Cancer and Chemotherapy, run by University of Basrah.
Trial summary
compare the effectiveness sesame oil, aloe Vera gel, and nitroglycerin ointment prevention of phlebitis. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Cancer, Chemotherapy
- What is being tested?
- Sesame Oil, Aloe vera gel and nitroglycerin ointment
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 190 participants
- Where
- No sites listed yet
- Study dates
- 11 May 2026to 20 Jul 2026
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- adult conscious patients of both gender.
- Patients receiving chemotherapy antimetabolites (5-fluorouracil).
- Patients receiving chemotherapy alkylating agents (Cisplatin).
- Patients receiving chemotherapy through peripheral IV cannula.
- Patients breast cancer colon cancer.
Who cannot join
- Phlebitis has already appeared at the IV infusion site.
- Patients using port or central venous catheters to administer chemotherapy. - Patient radiation therapy, immunity therapy and palliative therapy
- Patients receiving chemotherapy (antitumor antibiotics, plant alkaloids).
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Comparing of Sesame Oil, Nitroglycerin Ointment, and Aloe Vera Gel on Prevention of Phlebitis Induced by Chemotherapy
compare the effectiveness sesame oil, aloe Vera gel, and nitroglycerin ointment prevention of phlebitis.
Read the detailed description
One of the most frequent operations carried out by junior nursing professionals is peripheral intravenous cannulation. Understanding the peripheral intravenous cannulation process is crucial in light of this.
Intravenous cannulation is a challenging procedure that carries a considerable risk of complications. Pain is worsened by complications and side effects related to the cannula, such as superficial phlebitis and infiltration. If the cannulation fails or is disregarded, it might result in further treatment and transfer delays and possibly worse patient outcomes. Peripheral intravenous therapy can cause the unpleasant side effect known as chemotherapyinduced phlebitis (CIP), especially after chemotherapy. To prevent the development of (CIP), the nurses take preventative measures. The most frequent side effect of intravenous chemotherapy drug injection is vein inflammation, or phlebitis, which interferes with the treatment. Nurses have been very concerned about preventing any damage to the veins from phlebitis because they are responsible for administering chemotherapy.
Important of the study: One of the biggest health issues facing modern society is cancer. According to the World Health Organization, there is a steady upward trend in cancer incidence worldwide. Worldwide death rates from cancer are 9% due to all forms of the disease. After heart problems, cancer is the second most common cause of death in developed countries, accounting for 19% of deaths. In developing countries, cancer is the fourth most common cause of death and a contributing factor in 6% of deaths. Statistics show that over 5 million deaths worldwide are related to cancer, out of an estimated 50 million deaths annually. Chemotherapy is one of many treatment modalities used to fight cancer; it is considered a systemic approach. This method makes use of drugs that are cytotoxic. Cancer is the second leading cause of death in Iraq and the fourth leading cause in the Eastern Mediterranean region, and its incidence is rising quickly. The aging population trend, improved identification and registration, and-most importantly-increased exposure to risk factors are all contributing factors to the observed increase. Smoking is the most significant of these risk factors. Unhealthy eating habits, less exercise, other behavioral changes in lifestyle, pollution, and higher exposure to carcinogens from agriculture and industry are additional factors. With a 5.3% mortality3 rate in 2013, colorectal cancer was Iraq's ninth leading cause of death, accounting for 8341 cancerrelated deaths overall-roughly 4301 for men and 4040 for women. The National Plan of Cancer Control states that. Over the last 30 years of the 20th century, the global cancer epidemic has doubled; by 2030, it is predicted to nearly triple; and by 2050, it will increase threefold.
Chemotherapy, as a therapeutic intervention for malignancies, plays a crucial role in prolonging patients' survival rates. Nevertheless, the pharmacological agents employed in chemotherapy are associated with a myriad of deleterious side effects. Among these adverse reactions, phlebitis is a notable complication. Chemotherapy medications can harm the skin's and nails' rapidly proliferating cells. Even though some of these changes may hurt, the majority are benign and don't need medical attention. Many of them will recover after their chemotherapy course is over. Major skin changes, however, must be addressed immediately because they may result in permanent harm. small alterations to the skin When receiving chemotherapy via an IV, darker veins may appear darker and exhibit itching, dryness, redness, rashes, and peeling.
It is the most widely used way to administer chemotherapy for cancer. administered either peripherally or via central venous catheters. Absorption has greater dependability. In addition to minimizing the need for repeated injections, this route is necessary for the administration of vesicants. The risk of infection and potentially fatal sepsis is a significant side effect of intravenous (IV) chemotherapy since it allows direct access to the circulatory system.
Is the unintentional release of irritant or vesicant chemotherapy medications into the surrounding tissues at the intravenous site . A chemical that causes blisters and tissue damage is known as a vesicant. Whatever causes venous pain at the vein's location and along its length, whether or not an inflammatory response occurs us, is considered an irritant. Sloughing off of tissue, infection, pain, and impaired movement of an limb are among the possible injuries.
Using a peripheral intravenous cannula is one of a hospital nurse's most crucial responsibilities. The most common ways to get fluids into the bloods tream for chemotherapy and blood transfusions or their derivatives are intravenous therapy and fluid administration, regardless of whether the patient is being treated in an emergency room or is admitted to the hospital.4 Phlebitis occurred in as many as 70% of patients undergoing intravenous chemotherapy. Phlebitis can result in deep vein thrombosis and superficial vein thrombosis, both of which can kill and disable cancer patients. According to one study, 35-65% of cancer patients experience phlebitis brought on by chemotherapy.
Approximately 70% to 90% of patients undergoing chemotherapy will develop chemotherapyinduced phlebitis (CIP). Over half of patients die from phlebitis related to catheter use. The range of 1.3% to 61.2% represents the incidence of phlebitis. Sesame oil is important in preventing phlebitis because it can be absorbed through the skin. suggested as a preventative measure against chemotherapy-induced phlebitis. Further investigation is advised, preferably in other hospital wards and with a larger sample size.
Sesame oil application is advised as a standard hospital treatment for patients receiving chemotherapy. It is possible to conduct a similar study with a large probability sample and in a variety of settings, allowing for greater generalization of the findings. partnering with other organizations to apply cold compresses and sesame oil as a preventative measure to lower chemotherapy-associated pneumonia (CIP) in patients. Patients with cancer should learn how to recognize and report any changes in their vein health. When compared to patients who did not apply topical sesame oil on the third, fifth, or seventh day, the application of local sesame oil greatly decreased the intensity of pain on those days. It was also shown that the application of topical sesame oil sped up the recovery and healing process. The effects of topical sesame oil application on the degree of pain following chemical and boiling water burns, as well as the effects of other medicinal plants on the degree of pain and phlebitis, are proposed. Putting a compress of aloe Vera on to treat phlebitis is a novel non-pharmacological therapy approach. Aloe Vera is beneficial because it won't cause extraversion due to its low electrolyte concentrate. Aloe Vera dramatically lowered the degree of phlebitis, according to research by Anggraeni et al. An earlier study on the effects of nitroglycerin ointment on phlebitis examined the differences in incidence of angiocath-induced superficial phlebitis between clobetasol and nitroglycerin ointments. The incidence of catheter-induced phlebitis was observed to be decreased by nitroglycerin ointment, and its use was advised to avoid phlebitis in patients who require long-term5 angiocath usage. Avazeh et al. looked into the effects of topical nitroglycerine treatment on the incidence and severity of phlebitis caused by catheters. Breast cancer, which affects both men and women, is typified by the aberrant proliferation of cancerous cells in the mammary glands. Breast cancer is second in terms of overall frequency among all cancers in women, with around 1.7 million new cases identified in 2012. It is also the leading cause of cancer-related deaths among women worldwide. This accounts for roughly 12% of all newly diagnosed instances of cancer and 25% of. Globally, breast cancer is the most frequent cancer to affect women. It is the most common malignancy among Iraqis overall and accounts for almost one-third of all female cancer cases that are reported. For the past 20 years, breast cancer has been the most common malignancy among Iraqis, indicating a tendency for the disease to strike younger women. Because to early identification and effective treatment, 89% of women with breast cancer in western nations were still alive five years after receiving their diagnosis, despite the disease's high incidence rates.
The second most prevalent cause of cancer-related mortality globally and the third most common kind of cancer is colorectal cancer. Patients who have a high chance of recurrence are treated with adjuvant chemotherapy. According to GLOBOCAN 2018 data, colorectal cancer (CRC) ranks fourth in terms of diagnosis frequency and third globally in terms of fatality. The incidence of CRC varies greatly between industrialized and developing nations. CRC accounts for 6% of all cancer cases reported in Iraq.
Family history and first-degree relatives with colorectal cancer are considered high risk factors. Conversely, intermediate risk factors consist of increasing consumption of red meat, obesity, sedentary lifestyles, low consumption of fruits and vegetables, and smoking. Variations in exposure to those risk variables could lead to notable differences in cancer incidence between nations. Phlebitis in patients has been associated with the regularly used chemotherapy medication cisplatin, mostly because to its inflammatory and procoagulant characteristics. Understanding these pathways is essential to improving patient outcomes. Red blood cell procoagulant activity is increased by cisplatin treatment and is highly linked with phosphatidylserine exposure. This could contribute to the etiology of thrombophilia in breast cancer patients after treatment with cisplatin. To ensure the suppression of cancer cells that might have persisted or spread to other organs, 5- fluorouracil (5-FU) is a necessary component of systemic chemotherapy for colorectal cancer (CRC). For colorectal cancer, 5-fluorouracil (5FU) is the most frequently recommended medication. Nevertheless, recurrence after 5-FU therapy is unfortunately common and could be linked to p53-mediated WNT/β-catenin signaling, which enriches cancer stem cells in both adjuvant and palliative settings. The illness known as superficial phlebitis, which is characterized by vein inflammation, is linked to 5-fluorouracil (5-FU). Impairment of microvascular responsiveness, oxidative stress, and endothelial dysfunction are the fundamental mechanisms causing this negative effect. 5-FU causes endothelial cell injury, which raises thrombogenicity and inflammation. subsequent phlebitis, as platelet aggregation and clot formation are encouraged by the injured endothelium. This endothelial damage can 48 lead to arterial blockage because the medication increases superoxide anion levels, which lower endothelial cells' antioxidant capacity and worsen inflammation and cellular damage. One important element in the pathophysiology of vascular problems, such as phlebitis, is oxidative stress. This study's primary objective is to close this gap by comparing three methods in a clinical trial and identifying the most successful one for lowering the risk of phlebitis. among patients receiving intravenous catheter chemotherapy. Lack of proposed definitive methods for phlebitis treatment need for low-cost and novel prevention methods. Lack of comparison with other anti-phlebitis treatments. Limited discussion on potential confounding variables affecting results.
- Conditions
- Cancer, Chemotherapy
- Being tested
- Sesame Oil, Aloe vera gel, Control, nitroglycerin ointment
- Keywords
- sesame oil, aloe Vera gel, nitroglycerin ointment, phlebitis
- Medical subject headings
- Neoplasms, Phlebitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Sesame OilBiological
Also called Yellow
10 drops (3 mL) of 100% pure sesame oil in a circular motion for 5 minutes within 10 cm on the anterior forearm of the chemotherapy patient. T
Aloe vera gelBiological
Also called green
soak the skin in 5 cc of Aloe vera gel, drawn with a syringe, in a circular motion for 20 minutes within 10 cm on the anterior forearm of the chemotherapy patient.
ControlOther
Also called white
without any intervention
nitroglycerin ointmentBiological
The researchers will apply nitroglycerin ointment in a circular motion for 5 minutes over a 10 cm area on the anterior forearm of the chemotherapy patient.
| Study group | Role | What they receive |
|---|---|---|
| sesame oil | Experimental | Sesame oil application is advised as a standard hospital treatment for patients receiving chemotherapy. It is possible to conduct a similar study with a large probability sample and in a variety of settings, allowing for greater generalization of the findings. The researchers will be applied 10 drops (3 mL) of 100% pure sesame oil in a circular motion for 5 minutes within 10 cm on the anterior forearm of the chemotherapy patient. They then gradually spread the oil around 10 cm toward the arm of the study group to improve absorption. Each 12 hours wasapplied 2-time morning and night. Record the frequency of phlebitis in the 24 and 48 hours after the intervention. Receives: Biological: Sesame Oil |
| Aloe Vera gel | Experimental | The researcher will soak the skin in 5 cc of Aloe vera gel, drawn with a syringe, in a circular motion for 20 minutes within 10 cm on the anterior forearm of the chemotherapy patient. They then gradually spread the gel around 10 cm toward the arm of the study group to improve absorption. Each 12 hours, 2 time morning and night, record the frequency of phlebitis in the 24 hours after the intervention. Receives: Biological: Aloe vera gel |
| nitroglycerin ointment | Experimental | The researchers will apply nitroglycerin ointment in a circular motion for 5 minutes over a 10 cm area on the anterior forearm of the chemotherapy patient. They then gradually spread the oil around 10 cm toward the arm of the study group to improve absorption. Each 12 hours, a 2-time morning and night record the frequency of phlebitis in the 24 and 48 hours after the intervention. Receives: Biological: nitroglycerin ointment |
| control | Other | without any intervention Receives: Other: Control |
What is being measured
The primary outcome is the main question the study is designed to answer.
Phlebitis Scale
Multiple measurements will be aggregated to arrive at one reported value (phlebitis) that consists of five symptom grades were included in the chemotherapy-induced phlebitis severity scale, ranging from zero to four in severity. The National Cancer Institute Common Terminology Criteria for Adverse Events version 4 (NCI-CTCAE) (41). Which is widely used by clinical oncologists, served as the basis for the selection of grading levels. Grade zero denotes no symptoms); (grade one mild), ( grade two moderate), ( grade three marked) (and grade four severe).
Measured: 24-48 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jan 2026
- Study start11 May 2026 (estimated)
- Primary completion20 Jun 2026 (estimated)
- Study completion20 Jul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (39)Papers the sponsor has linked to this study.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- True experimental design (comparative) this type of design allows the researcher to understand the best cause-and-effect relationship between independent variables (sesame oil, aloe Vera gel , nitroglycerin ointment) and dependent variables (phlebitis), among patient receiving chemotherapy(antimetabolites 5- fluorouracil , alkylating agents Cisplatin) and which intervention is more effective
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 190 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Basrah
- Sponsor type
- University, hospital or other
- Collaborators
- University of Baghdad
- Responsible party
- Principal investigator, Ali Malik Tiryag, University of Basrah
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07346677
- Sponsor's protocol ID
- Prevention of Phlebitis
- Status last verified
- Apr 2026
- First submitted
- 6 Dec 2025
- Last updated
- 28 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Publications
Shakhbazova A, Marsch AF. Systemic 5-fluorouracil induced lupus erythematosus: a review of the literature. Dermatol Online J. 2019 Nov 15;25(11):13030/qt3nw0p7hn.
PubMed 32045142Yousef MI, Saad AA, El-Shennawy LK. Protective effect of grape seed proanthocyanidin extract against oxidative stress induced by cisplatin in rats. Food Chem Toxicol. 2009 Jun;47(6):1176-1183. doi: 10.1016/j.fct.2009.02.007.
PubMed 19425235Kadoyama K, Miki I, Tamura T, Brown JB, Sakaeda T, Okuno Y. Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations. Int J Med Sci. 2012;9(1):33-9. doi: 10.7150/ijms.9.33. Epub 2011 Nov 17.
PubMed 22211087Tsimberidou AM, Braiteh F, Stewart DJ, Kurzrock R. Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial. J Clin Oncol. 2009 Dec 20;27(36):6243-50. doi: 10.1200/JCO.2009.23.6018. Epub 2009 Oct 13.
PubMed 19826112Sudhakar S, Jacob A, Hegde NN, Chaudhary RK, Mateti UV, Shetty V. Evaluation of chemotherapy infusion and phlebitis among cancer patients: A prospective observational single-center study. J Oncol Pharm Pract. 2023 Dec;29(8):1944-1950. doi: 10.1177/10781552231161517. Epub 2023 Mar 5.
PubMed 36872649Outcomes of Patients with Chronic Lymphocytic Leukemia Treated with Chemotherapy in Middle Euphrates Region of Iraq: Data from Developing CountryMjali A. 2020;12
Johnson CM, Wei C, Ensor JE, Smolenski DJ, Amos CI, Levin B, Berry DA. Meta-analyses of colorectal cancer risk factors. Cancer Causes Control. 2013 Jun;24(6):1207-22. doi: 10.1007/s10552-013-0201-5. Epub 2013 Apr 6.
PubMed 23563998Some Facts About Cancers in Karbala province of Iraq, 2012-2020Mjali A, Baroodi B. Asian Pacific Journal of Cancer Care.2020;5.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
PubMed 30207593Argiles G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, Laurent-Puig P, Quirke P, Yoshino T, Taieb J, Martinelli E, Arnold D; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Oct;31(10):1291-1305. doi: 10.1016/j.annonc.2020.06.022. Epub 2020 Jul 20. No abstract available.
PubMed 32702383Iraqi Cancer Board: Results of the Iraqi Cancer Registry 2011. Baghdad, Iraqi Cancer Registry Center: Ministry of Health, 2013.
Alwan NA. Breast cancer: demographic characteristics and clinico-pathological presentation of patients in Iraq. East Mediterr Health J. 2010 Nov;16(11):1159-64.
PubMed 21218740International Agency for Cancer Research (IARC); World health Organization: GLOBOCAN 2012 v1.1, Cancer Incidence and Mortality Worldwide: IARC Cancer Base, 2012, No. 11 [Online], Available from: http://globocan.iarc.fr , accessed on 16/05/2016.
American Cancer society (A): Breast cancer:Facts and Figures 2015-2016. Atlanta:Author, 2016, [Online], Available from: www.cancer.org/cancerfactsstatistics/acspc-046381 , accessed on 26/01/2016.
Akbari H, Raufi S, Hekmat po D , Anbari K (2014). Comparaing the effect of Nitroglycerin and Clobetazol Ointments on Prevention of Superficial Intravenous Catheter Induced Phlebitis. Evide Based Care, 4, 71-80
Study at a glance
From the registry record, last updated by the sponsor on 28 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparing of Sesame Oil, Nitroglycerin Ointment, and Aloe Vera Gel on Prevention of Phlebitis Induced by Chemotherapy
- ClinicalTrials.gov ID
- NCT07346677
- Acronym / sponsor ID
- Prevention of Phlebitis
- Conditions
- Cancer, Chemotherapy
- Keywords
- sesame oil, aloe Vera gel, nitroglycerin ointment, phlebitis
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 190 participants (estimated)
- Lead sponsor
- University of BasrahUniversity, hospital or other
- Collaborators
- University of Baghdad
- Study start
- 11 May 2026 (estimated)
- Primary completion
- 20 Jun 2026 (estimated)
- Study completion
- 20 Jul 2026 (estimated)
- First posted
- 16 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
compare the effectiveness sesame oil, aloe Vera gel, and nitroglycerin ointment prevention of phlebitis.
Detailed description
One of the most frequent operations carried out by junior nursing professionals is peripheral intravenous cannulation. Understanding the peripheral intravenous cannulation process is crucial in light of this.
Intravenous cannulation is a challenging procedure that carries a considerable risk of complications. Pain is worsened by complications and side effects related to the cannula, such as superficial phlebitis and infiltration. If the cannulation fails or is disregarded, it might result in further treatment and transfer delays and possibly worse patient outcomes. Peripheral intravenous therapy can cause the unpleasant side effect known as chemotherapyinduced phlebitis (CIP), especially after chemotherapy. To prevent the development of (CIP), the nurses take preventative measures. The most frequent side effect of intravenous chemotherapy drug injection is vein inflammation, or phlebitis, which interferes with the treatment. Nurses have been very concerned about preventing any damage to the veins from phlebitis because they are responsible for administering chemotherapy.
Important of the study: One of the biggest health issues facing modern society is cancer. According to the World Health Organization, there is a steady upward trend in cancer incidence worldwide. Worldwide death rates from cancer are 9% due to all forms of the disease. After heart problems, cancer is the second most common cause of death in developed countries, accounting for 19% of deaths. In developing countries, cancer is the fourth most common cause of death and a contributing factor in 6% of deaths. Statistics show that over 5 million deaths worldwide are related to cancer, out of an estimated 50 million deaths annually. Chemotherapy is one of many treatment modalities used to fight cancer; it is considered a systemic approach. This method makes use of drugs that are cytotoxic. Cancer is the second leading cause of death in Iraq and the fourth leading cause in the Eastern Mediterranean region, and its incidence is rising quickly. The aging population trend, improved identification and registration, and-most importantly-increased exposure to risk factors are all contributing factors to the observed increase. Smoking is the most significant of these risk factors. Unhealthy eating habits, less exercise, other behavioral changes in lifestyle, pollution, and higher exposure to carcinogens from agriculture and industry are additional factors. With a 5.3% mortality3 rate in 2013, colorectal cancer was Iraq's ninth leading cause of death, accounting for 8341 cancerrelated deaths overall-roughly 4301 for men and 4040 for women. The National Plan of Cancer Control states that. Over the last 30 years of the 20th century, the global cancer epidemic has doubled; by 2030, it is predicted to nearly triple; and by 2050, it will increase threefold.
Chemotherapy, as a therapeutic intervention for malignancies, plays a crucial role in prolonging patients' survival rates. Nevertheless, the pharmacological agents employed in chemotherapy are associated with a myriad of deleterious side effects. Among these adverse reactions, phlebitis is a notable complication. Chemotherapy medications can harm the skin's and nails' rapidly proliferating cells. Even though some of these changes may hurt, the majority are benign and don't need medical attention. Many of them will recover after their chemotherapy course is over. Major skin changes, however, must be addressed immediately because they may result in permanent harm. small alterations to the skin When receiving chemotherapy via an IV, darker veins may appear darker and exhibit itching, dryness, redness, rashes, and peeling.
It is the most widely used way to administer chemotherapy for cancer. administered either peripherally or via central venous catheters. Absorption has greater dependability. In addition to minimizing the need for repeated injections, this route is necessary for the administration of vesicants. The risk of infection and potentially fatal sepsis is a significant side effect of intravenous (IV) chemotherapy since it allows direct access to the circulatory system.
Is the unintentional release of irritant or vesicant chemotherapy medications into the surrounding tissues at the intravenous site . A chemical that causes blisters and tissue damage is known as a vesicant. Whatever causes venous pain at the vein's location and along its length, whether or not an inflammatory response occurs us, is considered an irritant. Sloughing off of tissue, infection, pain, and impaired movement of an limb are among the possible injuries.
Using a peripheral intravenous cannula is one of a hospital nurse's most crucial responsibilities. The most common ways to get fluids into the bloods tream for chemotherapy and blood transfusions or their derivatives are intravenous therapy and fluid administration, regardless of whether the patient is being treated in an emergency room or is admitted to the hospital.4 Phlebitis occurred in as many as 70% of patients undergoing intravenous chemotherapy. Phlebitis can result in deep vein thrombosis and superficial vein thrombosis, both of which can kill and disable cancer patients. According to one study, 35-65% of cancer patients experience phlebitis brought on by chemotherapy.
Approximately 70% to 90% of patients undergoing chemotherapy will develop chemotherapyinduced phlebitis (CIP). Over half of patients die from phlebitis related to catheter use. The range of 1.3% to 61.2% represents the incidence of phlebitis. Sesame oil is important in preventing phlebitis because it can be absorbed through the skin. suggested as a preventative measure against chemotherapy-induced phlebitis. Further investigation is advised, preferably in other hospital wards and with a larger sample size.
Sesame oil application is advised as a standard hospital treatment for patients receiving chemotherapy. It is possible to conduct a similar study with a large probability sample and in a variety of settings, allowing for greater generalization of the findings. partnering with other organizations to apply cold compresses and sesame oil as a preventative measure to lower chemotherapy-associated pneumonia (CIP) in patients. Patients with cancer should learn how to recognize and report any changes in their vein health. When compared to patients who did not apply topical sesame oil on the third, fifth, or seventh day, the application of local sesame oil greatly decreased the intensity of pain on those days. It was also shown that the application of topical sesame oil sped up the recovery and healing process. The effects of topical sesame oil application on the degree of pain following chemical and boiling water burns, as well as the effects of other medicinal plants on the degree of pain and phlebitis, are proposed. Putting a compress of aloe Vera on to treat phlebitis is a novel non-pharmacological therapy approach. Aloe Vera is beneficial because it won't cause extraversion due to its low electrolyte concentrate. Aloe Vera dramatically lowered the degree of phlebitis, according to research by Anggraeni et al. An earlier study on the effects of nitroglycerin ointment on phlebitis examined the differences in incidence of angiocath-induced superficial phlebitis between clobetasol and nitroglycerin ointments. The incidence of catheter-induced phlebitis was observed to be decreased by nitroglycerin ointment, and its use was advised to avoid phlebitis in patients who require long-term5 angiocath usage. Avazeh et al. looked into the effects of topical nitroglycerine treatment on the incidence and severity of phlebitis caused by catheters. Breast cancer, which affects both men and women, is typified by the aberrant proliferation of cancerous cells in the mammary glands. Breast cancer is second in terms of overall frequency among all cancers in women, with around 1.7 million new cases identified in 2012. It is also the leading cause of cancer-related deaths among women worldwide. This accounts for roughly 12% of all newly diagnosed instances of cancer and 25% of. Globally, breast cancer is the most frequent cancer to affect women. It is the most common malignancy among Iraqis overall and accounts for almost one-third of all female cancer cases that are reported. For the past 20 years, breast cancer has been the most common malignancy among Iraqis, indicating a tendency for the disease to strike younger women. Because to early identification and effective treatment, 89% of women with breast cancer in western nations were still alive five years after receiving their diagnosis, despite the disease's high incidence rates.
The second most prevalent cause of cancer-related mortality globally and the third most common kind of cancer is colorectal cancer. Patients who have a high chance of recurrence are treated with adjuvant chemotherapy. According to GLOBOCAN 2018 data, colorectal cancer (CRC) ranks fourth in terms of diagnosis frequency and third globally in terms of fatality. The incidence of CRC varies greatly between industrialized and developing nations. CRC accounts for 6% of all cancer cases reported in Iraq.
Family history and first-degree relatives with colorectal cancer are considered high risk factors. Conversely, intermediate risk factors consist of increasing consumption of red meat, obesity, sedentary lifestyles, low consumption of fruits and vegetables, and smoking. Variations in exposure to those risk variables could lead to notable differences in cancer incidence between nations. Phlebitis in patients has been associated with the regularly used chemotherapy medication cisplatin, mostly because to its inflammatory and procoagulant characteristics. Understanding these pathways is essential to improving patient outcomes. Red blood cell procoagulant activity is increased by cisplatin treatment and is highly linked with phosphatidylserine exposure. This could contribute to the etiology of thrombophilia in breast cancer patients after treatment with cisplatin. To ensure the suppression of cancer cells that might have persisted or spread to other organs, 5- fluorouracil (5-FU) is a necessary component of systemic chemotherapy for colorectal cancer (CRC). For colorectal cancer, 5-fluorouracil (5FU) is the most frequently recommended medication. Nevertheless, recurrence after 5-FU therapy is unfortunately common and could be linked to p53-mediated WNT/β-catenin signaling, which enriches cancer stem cells in both adjuvant and palliative settings. The illness known as superficial phlebitis, which is characterized by vein inflammation, is linked to 5-fluorouracil (5-FU). Impairment of microvascular responsiveness, oxidative stress, and endothelial dysfunction are the fundamental mechanisms causing this negative effect. 5-FU causes endothelial cell injury, which raises thrombogenicity and inflammation. subsequent phlebitis, as platelet aggregation and clot formation are encouraged by the injured endothelium. This endothelial damage can 48 lead to arterial blockage because the medication increases superoxide anion levels, which lower endothelial cells' antioxidant capacity and worsen inflammation and cellular damage. One important element in the pathophysiology of vascular problems, such as phlebitis, is oxidative stress. This study's primary objective is to close this gap by comparing three methods in a clinical trial and identifying the most successful one for lowering the risk of phlebitis. among patients receiving intravenous catheter chemotherapy. Lack of proposed definitive methods for phlebitis treatment need for low-cost and novel prevention methods. Lack of comparison with other anti-phlebitis treatments. Limited discussion on potential confounding variables affecting results.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 4
- Model description
- True experimental design (comparative) this type of design allows the researcher to understand the best cause-and-effect relationship between independent variables (sesame oil, aloe Vera gel , nitroglycerin ointment) and dependent variables (phlebitis), among patient receiving chemotherapy(antimetabolites 5- fluorouracil , alkylating agents Cisplatin) and which intervention is more effective
| Arm | Type | Receives |
|---|---|---|
| sesame oil | Experimental | Biological: Sesame OilSesame oil application is advised as a standard hospital treatment for patients receiving chemotherapy. It is possible to conduct a similar study with a large probability sample and in a variety of settings, allowing for greater generalization of the findings. The researchers will be applied 10 drops (3 mL) of 100% pure sesame oil in a circular motion for 5 minutes within 10 cm on the anterior forearm of the chemotherapy patient. They then gradually spread the oil around 10 cm toward the arm of the study group to improve absorption. Each 12 hours wasapplied 2-time morning and night. Record the frequency of phlebitis in the 24 and 48 hours after the intervention. |
| Aloe Vera gel | Experimental | Biological: Aloe vera gelThe researcher will soak the skin in 5 cc of Aloe vera gel, drawn with a syringe, in a circular motion for 20 minutes within 10 cm on the anterior forearm of the chemotherapy patient. They then gradually spread the gel around 10 cm toward the arm of the study group to improve absorption. Each 12 hours, 2 time morning and night, record the frequency of phlebitis in the 24 hours after the intervention. |
| nitroglycerin ointment | Experimental | Biological: nitroglycerin ointmentThe researchers will apply nitroglycerin ointment in a circular motion for 5 minutes over a 10 cm area on the anterior forearm of the chemotherapy patient. They then gradually spread the oil around 10 cm toward the arm of the study group to improve absorption. Each 12 hours, a 2-time morning and night record the frequency of phlebitis in the 24 and 48 hours after the intervention. |
| control | Other | Other: Controlwithout any intervention |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (5 listed)
- adult conscious patients of both gender.
- Patients receiving chemotherapy antimetabolites (5-fluorouracil).
- Patients receiving chemotherapy alkylating agents (Cisplatin).
- Patients receiving chemotherapy through peripheral IV cannula.
- Patients breast cancer colon cancer.
Key exclusion criteria (3 listed)
- Phlebitis has already appeared at the IV infusion site.
- Patients using port or central venous catheters to administer chemotherapy. - Patient radiation therapy, immunity therapy and palliative therapy
- Patients receiving chemotherapy (antitumor antibiotics, plant alkaloids).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Sesame OilAlso: Yellow10 drops (3 mL) of 100% pure sesame oil in a circular motion for 5 minutes within 10 cm on the anterior forearm of the chemotherapy patient. T | Biological | sesame oil |
| Aloe vera gelAlso: greensoak the skin in 5 cc of Aloe vera gel, drawn with a syringe, in a circular motion for 20 minutes within 10 cm on the anterior forearm of the chemotherapy patient. | Biological | Aloe Vera gel |
| ControlAlso: whitewithout any intervention | Other | control |
| nitroglycerin ointmentThe researchers will apply nitroglycerin ointment in a circular motion for 5 minutes over a 10 cm area on the anterior forearm of the chemotherapy patient. | Biological | nitroglycerin ointment |
Primary outcome
Phlebitis Scale
Time frame: 24-48 hours
Multiple measurements will be aggregated to arrive at one reported value (phlebitis) that consists of five symptom grades were included in the chemotherapy-induced phlebitis severity scale, ranging from zero to four in severity. The National Cancer Institute Common Terminology Criteria for Adverse Events version 4 (NCI-CTCAE) (41). Which is widely used by clinical oncologists, served as the basis for the selection of grading levels. Grade zero denotes no symptoms); (grade one mild), ( grade two moderate), ( grade three marked) (and grade four severe).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Apr 2026.
- Results publication: PubMed 32045142Shakhbazova A, Marsch AF. Systemic 5-fluorouracil induced lupus erythematosus: a review of the literature. Dermatol Online J. 2019 Nov 15;25(11):13030/qt3nw0p7hn.
- Results publication: PubMed 19425235Yousef MI, Saad AA, El-Shennawy LK. Protective effect of grape seed proanthocyanidin extract against oxidative stress induced by cisplatin in rats. Food Chem Toxicol. 2009 Jun;47(6):1176-1183. doi: 10.1016/j.fct.2009.02.007.
- Results publication: PubMed 22211087Kadoyama K, Miki I, Tamura T, Brown JB, Sakaeda T, Okuno Y. Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations. Int J Med Sci. 2012;9(1):33-9. doi: 10.7150/ijms.9.33. Epub 2011 Nov 17.
- Results publication: PubMed 19826112Tsimberidou AM, Braiteh F, Stewart DJ, Kurzrock R. Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial. J Clin Oncol. 2009 Dec 20;27(36):6243-50. doi: 10.1200/JCO.2009.23.6018. Epub 2009 Oct 13.
- Results publication: PubMed 36872649Sudhakar S, Jacob A, Hegde NN, Chaudhary RK, Mateti UV, Shetty V. Evaluation of chemotherapy infusion and phlebitis among cancer patients: A prospective observational single-center study. J Oncol Pharm Pract. 2023 Dec;29(8):1944-1950. doi: 10.1177/10781552231161517. Epub 2023 Mar 5.
- Results publicationOutcomes of Patients with Chronic Lymphocytic Leukemia Treated with Chemotherapy in Middle Euphrates Region of Iraq: Data from Developing CountryMjali A. 2020;12
- Results publication: PubMed 23563998Johnson CM, Wei C, Ensor JE, Smolenski DJ, Amos CI, Levin B, Berry DA. Meta-analyses of colorectal cancer risk factors. Cancer Causes Control. 2013 Jun;24(6):1207-22. doi: 10.1007/s10552-013-0201-5. Epub 2013 Apr 6.
- Results publicationSome Facts About Cancers in Karbala province of Iraq, 2012-2020Mjali A, Baroodi B. Asian Pacific Journal of Cancer Care.2020;5.
- Results publication: PubMed 30207593Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
- Results publication: PubMed 32702383Argiles G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, Laurent-Puig P, Quirke P, Yoshino T, Taieb J, Martinelli E, Arnold D; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Oct;31(10):1291-1305. doi: 10.1016/j.annonc.2020.06.022. Epub 2020 Jul 20. No abstract available.
- Results publicationIraqi Cancer Board: Results of the Iraqi Cancer Registry 2011. Baghdad, Iraqi Cancer Registry Center: Ministry of Health, 2013.
- Results publication: PubMed 21218740Alwan NA. Breast cancer: demographic characteristics and clinico-pathological presentation of patients in Iraq. East Mediterr Health J. 2010 Nov;16(11):1159-64.
- Individual participant dataSharing planned: Yes
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Sesame Oil, Aloe vera gel and nitroglycerin ointment in people with Cancer and Chemotherapy, run by University of Basrah.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 28 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ali Malik Tiryag, Master (+9647811735332, ali.malik@uobasrah.edu.iq), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Phlebitis Scale (time frame: 24-48 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07346677, which also lists 39 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Apr 2026; AzTrials last refreshed its copy on 8 Nov 2026.